Posts tagged safety
Roth starts Zafgen at buy

Roth Capital Partners launched coverage of Zafgen (NASDAQ:ZFGN) with a “buy” rating and $9 price target. The stock closed at $4.90 on April 19.

Read More
BioSight completes Phase 1/2a leukemia trial

Closely-held BioSight has completed patient treatment in its ongoing Phase 1/2a clinical study of Astarabine in acute leukemia patients and expects to report final results in coming months.

The Phase 1/2a trial is an open-label study to evaluate the safety and efficacy of Astarabine as single agent in adults with acute myeloid leukemia (AML) and relapsed/refractory acute lymphoblastic leukemia (ALL).

Read More
Can-Fite submits Phase 3 RA trial protocol to EMA

Can-Fite BioPharma (NYSE MKT:CANF; TASE:CFBI) has submitted to the European Medicines Agency (EMA) a protocol design for a Phase 3 trial and registration plan for its lead compound, CF101, in the treatment of rheumatoid arthritis. The company previously had a pre-submission meeting with the EMA.

The global trial is expected to begin in either the second or third quarter of 2016. It will investigate the efficacy and safety of CF101 administered orally twice daily for 16 weeks to patients with active rheumatoid arthritis treated with conventional disease modifying drugs.

Read More
EyeGate Pharma Acquires Jade Therapeutics

EyeGate Pharmaceuticals (NASDAQ:EYEG) has acquired Jade Therapeutics, a closely-held company developing locally administered, polymer-based products designed to treat poorly-served ophthalmic indications.

Jade’s proprietary, cross-linked, bio-erodible hydrogel technology has demonstrated a variety of unique and beneficial characteristics, whether employed alone or as a sustained-release drug-delivery vehicle.

Read More
Soricimed posts positive SOR-C13 data in solid tumors

Closely-held Soricimed Biopharma has announced positive top-line results from a Phase 1 open-label, dose escalation study of its first-in-class peptide, SOR-C13, in subjects with advanced solid tumor cancers.

The primary goal of the study was to assess safety and tolerability of SOR-C13 in subjects with advanced carcinomas commonly known to express the TRPV6 channel and who had failed all previous anti-cancer treatments.  SOR-C13 is the first drug candidate targeting TRPV6 to enter human clinical trials.

Read More